Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling
暂无分享,去创建一个
John O. Miners | Pramod C. Nair | Matthew P. Doogue | J. Miners | B. Lewis | A. Somogyi | M. Doogue | J. Bowden | Andrew A. Somogyi | Benjamin C. Lewis | Subash S. Heran | Jeffrey J. Bowden | Subash S Heran
[1] Duan Li,et al. On Restart Procedures for the Conjugate Gradient Method , 2004, Numerical Algorithms.
[2] A. Somogyi,et al. The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. , 2013, British journal of clinical pharmacology.
[3] M. Shearer,et al. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 , 2004, Thrombosis and Haemostasis.
[4] Sean R. Eddy,et al. Profile hidden Markov models , 1998, Bioinform..
[5] J. Miners,et al. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.
[6] M. Shearer,et al. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1 , 2008, Journal of thrombosis and haemostasis : JTH.
[7] A. Rettie,et al. Pharmacogenomics of 4-hydroxycoumarin anticoagulants. , 2008, Drug metabolism reviews.
[8] C. Ponting,et al. Vitamin K epoxide reductase: homology, active site and catalytic mechanism. , 2004, Trends in biochemical sciences.
[9] Jeffrey P. Jones,et al. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. , 2005, Annual review of pharmacology and toxicology.
[10] T. Rapoport,et al. Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners , 2010, Proceedings of the National Academy of Sciences.
[11] Andreas Fregin,et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.
[12] R. Russell,et al. Amino‐Acid Properties and Consequences of Substitutions , 2003 .
[13] J. Halperin,et al. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. , 2009, Pharmacogenomics.
[14] Ajay N. Jain,et al. Parameter estimation for scoring protein-ligand interactions using negative training data. , 2006, Journal of medicinal chemistry.
[15] M. J. D. Powell,et al. Restart procedures for the conjugate gradient method , 1977, Math. Program..
[16] J. Miners,et al. Application of Homology Modeling to Generate CYP1A1 Mutants with Enhanced Activation of the Cancer Chemotherapeutic Prodrug Dacarbazine , 2011, Molecular Pharmacology.
[17] J. Oldenburg,et al. The Genetic Basis of Resistance to Anticoagulants in Rodents , 2005, Genetics.
[18] C. Deane,et al. CODA: A combined algorithm for predicting the structurally variable regions of protein models , 2001, Protein science : a publication of the Protein Society.
[19] M. Whirl‐Carrillo,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.
[20] A. Breckenridge,et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man , 1974, Clinical pharmacology and therapy.
[21] Leonardo Pardo,et al. Relation between sequence and structure in membrane proteins , 2013, Bioinform..
[22] Gunnar von Heijne,et al. Membrane Topology Mapping of Vitamin K Epoxide Reductase by in Vitro Translation/Cotranslocation* , 2005, Journal of Biological Chemistry.
[23] M. Ozelo,et al. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. , 2010, Thrombosis research.
[24] J. Miners,et al. The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily. , 2012, Pharmacology & therapeutics.
[25] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[26] J. Miners,et al. Identification of Residues That Confer Sugar Selectivity to UDP-Glycosyltransferase 3A (UGT3A) Enzymes* , 2012, The Journal of Biological Chemistry.
[27] J. Miners,et al. Interaction of sulphinpyrazone with warfarin , 2004, European Journal of Clinical Pharmacology.
[28] A. Biswas,et al. Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces. , 2013, Blood.
[29] T. Rapoport,et al. Structure of a bacterial homolog of vitamin K epoxide reductase , 2010, Nature.
[30] C. Müller,et al. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment , 2011, Journal of thrombosis and haemostasis : JTH.
[31] J. Miners,et al. Comparative homology modeling of human cytochrome P4501A1 (CYP1A1) and confirmation of residues involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme kinetic analysis. , 2007, Archives of biochemistry and biophysics.